GSK plc GSK announced that the FDA approved the expanded use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 18 to 49 years who are at a higher risk of ...

A phase 3b trial showed adjuvanted RSVPreF3 vaccination was immunogenic and safe for younger adults with chronic conditions at increased risk for RSV disease.

The ECDC, the infectious diseases watchdog, has asked for scientists to join its new panel on RSV as Europe begins to vaccinate its most vulnerable adults.

RSV in older adults remains a growing public health concern. Read more about surveillance gaps, vaccination policy, and prevention needs.

In a new clinical guideline, rapid practice points are presented for receipt of RSV protein subunit vaccines among adults.

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled trial ...

The FDA has approved a third respiratory syncytial virus vaccine for high-risk adults aged younger than 50 years — a ...

The shot's efficacy declined slightly compared with the levels of protection after one RSV season, but the new data suggests that the jab generally offers durable protection for adults ages 60 and ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of the virus. A booster dose one year after the initial shot failed to do ...

A landmark global trial shows that one dose of the RSVPreF3 OA vaccine protects older adults against serious RSV lung disease for three seasons, raising hopes for long-term protection with just a ...

—These investigators found that during a recent winter in England, symptoms and outcomes among older patients with RSV mimicked those seen with influenza. A new hospital-based surveillance study from ...

It’s a major cause of respiratory illness in all age groups, but young and old are at greatest risk.